J. Goldman & CO LP Crispr Therapeutics Ag Transaction History
J. Goldman & CO LP
- $3.75 Billion
- Q2 2025
A detailed history of J. Goldman & CO LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, J. Goldman & CO LP holds 27,200 shares of CRSP stock, worth $1.53 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
27,200Holding current value
$1.53 Million% of portfolio
0.04%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CRSP
# of Institutions
541Shares Held
68.6MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$574 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$316 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$208 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$184 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$160 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.4B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....